Department of Neuropsychopharmacology, Maj Institute of Pharmacology Polish Academy of Sciences, 31-343 Kraków, Poland.
Biomolecules. 2021 Dec 2;11(12):1813. doi: 10.3390/biom11121813.
Essential tremor (ET) is one of the most common neurological disorders that often affects people in the prime of their lives, leading to a significant reduction in their quality of life, gradually making them unable to independently perform the simplest activities. Here we show that current ET pharmacotherapy often does not sufficiently alleviate disease symptoms and is completely ineffective in more than 30% of patients. At present, deep brain stimulation of the motor thalamus is the most effective ET treatment. However, like any brain surgery, it can cause many undesirable side effects; thus, it is only performed in patients with an advanced disease who are not responsive to drugs. Therefore, it seems extremely important to look for new strategies for treating ET. The purpose of this review is to summarize the current knowledge on the pathomechanism of ET based on studies in animal models of the disease, as well as to present and discuss the results of research available to date on various substances affecting dopamine (mainly D3) or adenosine A1 receptors, which, due to their ability to modulate harmaline-induced tremor, may provide the basis for the development of new potential therapies for ET in the future.
特发性震颤(ET)是最常见的神经障碍之一,常发生于青壮年人群,导致其生活质量显著下降,逐渐使其无法独立完成最简单的活动。在这里,我们发现目前的 ET 药物治疗通常不能充分缓解疾病症状,而且在超过 30%的患者中完全无效。目前,丘脑底核深部脑刺激是治疗 ET 最有效的方法。然而,与任何脑部手术一样,它可能会引起许多不良的副作用;因此,仅对药物治疗无反应且疾病进展的患者进行。因此,寻找治疗 ET 的新策略似乎非常重要。本综述的目的是总结基于疾病动物模型的研究,目前对 ET 发病机制的认识,并介绍和讨论目前关于影响多巴胺(主要是 D3)或腺苷 A1 受体的各种物质的研究结果,由于它们能够调节苦杏仁素诱导的震颤,因此可能为未来开发治疗 ET 的新潜在疗法提供基础。